MCID: PRS045
MIFTS: 52

Prostatic Hypertrophy

Categories: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 15 71
Benign Prostatic Hypertrophy 71
Prostatic Hyperplasia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11132
UMLS 71 C0005001 C1739363 C2937421

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostatitis and prostatic hyperplasia, benign, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Selegiline and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include prostate, breast and testes, and related phenotypes are endocrine/exocrine gland and immune system

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 prostatitis 30.8 KLK3 ADRA1A ACP3
2 prostatic hyperplasia, benign 30.5 SRD5A1 SERPINA3 KLK3 AR ACP3
3 impotence 30.3 SRD5A1 KLK3 AR ADRA1D ADRA1A
4 prostatic adenoma 30.3 SRD5A1 SERPINA3 KLK3 ADRA1D ADRA1A
5 hypogonadism 29.9 KLK3 FGF8 CYP19A1 AR
6 prostate disease 29.7 SRD5A1 SERPINA3 KLK3 CYP19A1 AR ACP3
7 sexual disorder 29.4 KLK3 EPPIN AR ADRA1D ADRA1A
8 suppression of tumorigenicity 12 29.2 SERPINA3 KLK3 ESR1 EGFR EGF AR
9 gynecomastia 29.1 SRY SRD5A1 PGR KLK3 ESR1 CYP19A1
10 prostate cancer 27.6 SRD5A1 SERPINA3 PGR PCNA KLK3 FGF8
11 prostate adenoid cystic carcinoma 10.6 KLK3 AR
12 prostate leiomyoma 10.6 KLK3 AR
13 glassy cell carcinoma of the cervix 10.5 PGR ESR1
14 bartholin's gland adenoid cystic carcinoma 10.5 PGR ESR1
15 chronic tympanitis 10.5 PGR ESR1
16 bartholin's gland adenoma 10.5 PGR ESR1
17 granulomatous endometritis 10.5 PGR ESR1
18 bartholin's gland benign neoplasm 10.5 PGR ESR1
19 liver adenomatosis 10.5 PGR AR
20 vestibular gland benign neoplasm 10.5 PGR ESR1
21 breast juvenile papillomatosis 10.5 PGR ESR1
22 lung leiomyoma 10.5 PGR ESR1
23 vulvar syringoma 10.5 PGR ESR1
24 trigonitis 10.5 PGR ESR1
25 calcifying aponeurotic fibroma 10.5 PGR EGF
26 submandibular gland cancer 10.5 KLK3 AR
27 vagina leiomyosarcoma 10.5 PGR ESR1
28 prostatic acinar adenocarcinoma 10.5 KLK3 AR
29 adult type testicular granulosa cell tumor 10.5 PGR ESR1
30 adenoma 10.5
31 postmenopausal atrophic vaginitis 10.5 ESR1 CYP19A1
32 ovarian seromucinous carcinoma 10.5 PGR ESR1
33 breast papillary carcinoma 10.5 PGR ESR1
34 breast leiomyoma 10.5 PGR ESR1
35 benign metastasizing leiomyoma 10.5 PGR CYP19A1
36 intravenous leiomyomatosis 10.4 PGR ESR1
37 androgen insensitivity, partial 10.4 SRD5A1 CYP19A1 AR
38 alopecia, androgenetic, 1 10.4 SRD5A1 CYP19A1 AR
39 wolffian duct adenocarcinoma 10.4 ESR1 AR
40 acute cystitis 10.4
41 liver leiomyoma 10.4 PGR ESR1
42 comedo carcinoma 10.4 PGR ESR1
43 mammographic density 10.4 PGR ESR1 CYP19A1
44 vulvar leiomyoma 10.4 PGR ESR1
45 oncocytic breast carcinoma 10.4 PGR ESR1 AR
46 progesterone-receptor positive breast cancer 10.4 PGR ESR1 CYP19A1
47 hypertrophy of breast 10.4 PGR ESR1 CYP19A1
48 vaginal discharge 10.4 PGR ESR1 CYP19A1
49 lymphangiomatosis 10.4 PGR PCNA
50 endometriosis of ovary 10.4 PGR ESR1 CYP19A1

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show all 49)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Cystitis Cystitis Cystica
Epididymo-Orchitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Hydronephrosis Infected Hydrocele
Interstitial Cystitis Kidney Disease
Left Bundle Branch Hemiblock Lipoma of Spermatic Cord
Low Compliance Bladder Nephrolithiasis, X-Linked Recessive, with Renal Failure
Neurogenic Bladder Parkinson Disease, Late-Onset
Pelvic Varices Penile Disease
Peyronie's Disease Pinta Disease
Pneumoconiosis Postinflammatory Pulmonary Fibrosis
Prostate Calculus Prostate Cancer
Prostate Carcinoma in Situ Prostate Disease
Prostatitis Prostatocystitis
Renal Pelvis Carcinoma Right Bundle Branch Block
Silicosis Spermatocele
Ureter, Cancer of Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Tract Obstruction Varicocele
Vesicoureteral Reflux 1

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10 ACP3 AR CD36 CYP19A1 EGF EGFR
2 immune system MP:0005387 9.9 AR CD36 CYP19A1 EGF EGFR ESR1
3 muscle MP:0005369 9.61 ADRA1A ADRA1D AR CD36 CYP19A1 EGFR
4 reproductive system MP:0005389 9.32 ACP3 AR CYP19A1 EGF EGFR ESR1

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
2
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
3
Finasteride Approved Phase 4 98319-26-7 57363
4
Silodosin Approved Phase 4 160970-54-7
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Methyltestosterone Approved Phase 4 58-18-4 6010
7
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
8
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Testosterone enanthate Approved Phase 4 315-37-7 9416
11
Saw palmetto Approved, Experimental, Investigational Phase 4
12
Sodium citrate Approved, Investigational Phase 4 68-04-2
13
carbamide peroxide Approved Phase 4 124-43-6
14
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Tranexamic Acid Approved Phase 4 1197-18-8 5526
17
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
20
Mirabegron Approved Phase 4 223673-61-8 9865528
21
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
22
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Cimetropium Experimental, Investigational Phase 4 150521-16-7
27 Naftopidil Investigational Phase 4 57149-07-2
28
Fibrinolysin Investigational Phase 4 9004-09-5
29 Cola Phase 4
30 Anticonvulsants Phase 4
31 Bromides Phase 4
32 Adjuvants, Anesthesia Phase 4
33 Antiemetics Phase 4
34 Gastrointestinal Agents Phase 4
35 Butylscopolammonium Bromide Phase 4
36 Mydriatics Phase 4
37 Antibiotics, Antitubercular Phase 4
38 Mitogens Phase 4
39 Anesthetics, Local Phase 4
40 Muscarinic Antagonists Phase 4
41 Cholinergic Antagonists Phase 4
42 Solifenacin succinate Phase 4 242478-38-2
43 Parasympatholytics Phase 4
44 Anabolic Agents Phase 4
45 Testosterone 17 beta-cypionate Phase 4
46 Antineoplastic Agents, Hormonal Phase 4
47 Saw palmetto extract Phase 4
48 Platelet Aggregation Inhibitors Phase 4
49 Calcium, Dietary Phase 4
50 calcium channel blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 569)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones Unknown status NCT00451061 Phase 4 Alfuzosin;Tamsulosin
3 A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study) Unknown status NCT01218672 Phase 4
4 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
5 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
6 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
7 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
8 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
9 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
10 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
11 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
12 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
13 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
14 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
15 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
16 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
17 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
18 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
19 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
20 Safety and Efficacy of 8mg Once-daily Versus 4mg Twice-daily Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH ; 12-week, Double-blind, Randomized, Comparison, Multi-center Study Completed NCT01260129 Phase 4 Silodosin;Silodosin
21 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Completed NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
22 Dutasteride Treatment for the Reduction of Heavy Drinking Completed NCT01758523 Phase 4 Dutasteride;sugar pill
23 Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
24 Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety" Completed NCT00752869 Phase 4 dutasteride;placebo
25 Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance Completed NCT00108420 Phase 4 Prazosin
26 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
27 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
28 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Completed NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
29 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
30 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
31 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
32 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
33 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
34 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
35 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Completed NCT02034604 Phase 4 Naftofidil;Tamsulosin
36 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
37 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
38 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
39 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
40 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
41 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
42 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
43 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
44 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
45 An Open, Non-Comparative, Multicenter Study on the Sexual Function Improvement Following Treatment With Alfuzosin in Patients With Benign Prostate Hyperplasia Completed NCT00427882 Phase 4 ALFUZOSIN
46 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
47 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
48 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS
49 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
50 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

40
Prostate, Breast, Testes, Smooth Muscle, Bone, Kidney, Endothelial

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 16229)
# Title Authors PMID Year
1
High serum concentration of estradiol may be a risk factor of prostate enlargement in aging male in China. 61
29912660 2020
2
Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL? 61
30862227 2020
3
Letter to the editor regarding the article 'association between asthma and risk of benign prostatic hyperplasia: a retrospective population-based study'. 61
30879379 2020
4
Higher neural contribution underlying persistent lower urinary tract symptoms in men with Benign Prostatic Hyperplasia undergoing bladder outlet procedures. 61
31886434 2020
5
Quantitative bidimentional and Doppler ultrasound assessment of the effect of a GnRH antagonist on canine prostatic hyperplasia. 61
31901534 2020
6
Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo. 61
31756334 2020
7
NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer. 61
31758937 2020
8
Prostate Benign Diseases. 61
32015291 2020
9
Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-κB signaling pathway. 61
31829321 2020
10
Regulation of microRNAs by rape bee pollen on benign prostate hyperplasia in rats. 61
31733069 2020
11
Re: Alpha-Blockers with or without Phosphodiesterase Type 5 Inhibitor for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. 61
31710569 2020
12
The 11β-hydroxyandrostenedione pathway and C11-oxy C21 backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone. 61
31626910 2020
13
Critical Analysis of a Multicentric Experience with Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: Outcomes and Complications of Ten Years of Routine Clinical Practice. 61
32020749 2020
14
Smart spectrophotometric assessment of tamsulosin hydrochloride and tadalafil in their new pharmaceutical formulation for treatment of benign prostatic hyperplasia and erectile dysfunction. 61
31734571 2020
15
Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors. 61
32008083 2020
16
Assessment of the clinical efficacy of simultaneous transurethral resection of both bladder cancer and the prostate: a systematic review and meta-analysis. 61
32020826 2020
17
Stanniocalcin-1 protein expression profile and mechanisms in proliferation and cell death pathways in prostate cancer. 61
31816356 2020
18
Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice. 61
32016843 2020
19
Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. 61
31734349 2020
20
Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment. 61
31822449 2020
21
Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. 61
31079189 2020
22
The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate. 61
31487219 2020
23
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers. 61
32017934 2020
24
[Comparison of 180 W Greenlight-XPS laser vaporisation and transurethral resection of the prostate: comfort for patients and healthcare staff in clinical routine practice]. 61
32018335 2020
25
Anatomical study of the prostatic urethra using vinyl polysiloxane casts. 61
31825529 2020
26
Lasers in the surgical treatment of canine prostatic neoplasia and selected tumours of the male reproductive system. 61
32011789 2020
27
Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. 61
32029929 2020
28
Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis. 61
31801683 2020
29
Leptin promotes epithelial-mesenchymal transition in benign prostatic hyperplasia through downregulation of BAMBI. 61
31805276 2020
30
State of the Art of Thulium Laser Enucleation and Vapoenucleation of the Prostate: A Systematic Review. 61
31726185 2020
31
Activation of Prejunctional P2x2/3 Heterotrimers by ATP Enhances the Cholinergic Tone in Obstructed Human Urinary Bladders. 61
31636173 2020
32
Ex vivo fluorescence confocal microscopy: prostatic and periprostatic tissues atlas and evaluation of the learning curve. 61
31907606 2020
33
Alfuzosin and Its Effect on Ejaculatory Dysfunction: A Systematic Review. 61
32009306 2020
34
Inter-imaging accuracy of computed tomography, magnetic resonance imaging, and transrectal ultrasound in measuring prostate volume compared to the anatomic prostatic weight. 61
31905124 2020
35
The burden of urological disease in Zomba, Malawi: A needs assessment in a sub-Saharan tertiary care center. 61
31658013 2020
36
Improvements in Irritative Versus Obstructive Symptoms of the International Prostate Symptom Score After Prostatic Artery Embolization in 174 Patients, in a Single Center. 61
31897620 2020
37
Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. 61
31464384 2020
38
Editorial Comment from Dr Amano to Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. 61
31588586 2020
39
Editorial Comment from Dr Tanaka to Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. 61
31602710 2020
40
Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. 61
31937082 2020
41
The relationship of embolic particle size to patient outcomes in prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-regression. 61
32000985 2020
42
[Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction]. 61
32003186 2020
43
The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. 61
31977871 2020
44
Analysis of Prostate-Specific Antigen-Related Indexes, Neutrophil-to-Lymphocyte Ratio in Patients with Concurrent Benign Prostatic Hyperplasia and Histologic Prostatitis. 61
32013341 2020
45
Efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate in Individuals with Benign Prostatic Hyperplasia Continuously Administered Oral Anticoagulants or Antiplatelet Drugs. 61
31972178 2020
46
Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model. 61
31965289 2020
47
Upregulated circZMIZ1 promotes the proliferation of prostate cancer cells and is a valuable marker in plasma. 61
31686520 2020
48
Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer. 61
32013356 2020
49
Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis. 61
31892984 2020
50
The changing role of lasers in urologic surgery. 61
31724998 2020

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.69 PCNA KLK3 EGFR EGF AR
2
Show member pathways
12.56 PGR FGF8 ESR1 EGFR EGF
3 12.36 KLK3 FGF8 ESR1 EGFR EGF AR
4 11.86 ESR1 EGFR CYP19A1 AR
5 11.66 KLK3 EGFR AR
6
Show member pathways
11.64 PGR ESR1 AR
7 11.47 ESR1 EGFR EGF
8 11.33 SRY KLK3 AR
9 11.29 ESR1 EGFR CD36
10
Show member pathways
11.29 PGR ESR1 EGFR EGF
11
Show member pathways
11.24 KLK3 ESR1 AR
12
Show member pathways
11.19 SRD5A1 KLK3 EGFR EGF AR
13 10.68 EGFR EGF
14
Show member pathways
9.92 EGFR EGF
15 9.86 ESR1 CYP19A1

GO Terms for Prostatic Hypertrophy

Cellular components related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 SERPINA3 LGALS8 KLK3 EPPIN EGFR EGF

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.03 FGF8 EGFR EGF AR ADRA1D
2 positive regulation of gene expression GO:0010628 10.02 SRY FGF8 EGF CD36 AR
3 cell-cell signaling GO:0007267 9.92 PGR AR ADRA1D ADRA1A
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 FGF8 EGFR CD36 ADRA1A
5 positive regulation of protein kinase B signaling GO:0051897 9.86 FGF8 ESR1 EGFR EGF
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 ESR1 CD36 ADRA1D ADRA1A
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 FGF8 EGF CD36
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.77 ESR1 ADRA1D ADRA1A
9 steroid hormone mediated signaling pathway GO:0043401 9.75 PGR ESR1 AR
10 regulation of systemic arterial blood pressure GO:0003073 9.64 KLK3 AR
11 adrenergic receptor signaling pathway GO:0071875 9.63 ADRA1D ADRA1A
12 cellular response to estradiol stimulus GO:0071392 9.63 SRD5A1 ESR1 EGFR
13 response to estradiol GO:0032355 9.62 SRD5A1 PCNA ESR1 EGFR
14 cellular response to testosterone stimulus GO:0071394 9.61 SRD5A1 AR
15 regulation of toll-like receptor signaling pathway GO:0034121 9.6 ESR1 CD36
16 prostate gland growth GO:0060736 9.58 CYP19A1 AR
17 positive regulation of vasoconstriction GO:0045907 9.58 EGFR ADRA1D ADRA1A
18 negative regulation of ERBB signaling pathway GO:1901185 9.57 EGFR EGF
19 female genitalia development GO:0030540 9.55 SRD5A1 CYP19A1
20 androgen catabolic process GO:0006710 9.54 SRD5A1 CYP19A1
21 positive regulation of phosphorylation GO:0042327 9.54 EGFR EGF AR
22 morphogenesis of an epithelial fold GO:0060571 9.51 EGFR AR
23 diterpenoid metabolic process GO:0016101 9.49 SRD5A1 EGFR
24 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.48 ADRA1D ADRA1A
25 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.43 PGR AR
26 response to lipid GO:0033993 9.43 PCNA EGFR CD36
27 sex differentiation GO:0007548 9.33 SRY SRD5A1 AR
28 mammary gland alveolus development GO:0060749 9.13 ESR1 EGF AR
29 androgen metabolic process GO:0008209 8.8 SRD5A1 ESR1 CYP19A1

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.65 PGR PCNA ESR1 EGFR AR
2 ATPase binding GO:0051117 9.58 PGR ESR1 AR
3 steroid hormone receptor activity GO:0003707 9.5 PGR ESR1 AR
4 nitric-oxide synthase regulator activity GO:0030235 9.37 ESR1 EGFR
5 nuclear receptor activity GO:0004879 9.33 PGR ESR1 AR
6 alpha1-adrenergic receptor activity GO:0004937 8.96 ADRA1D ADRA1A
7 steroid binding GO:0005496 8.8 PGR ESR1 AR

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....